<4419> Finatext 1043 +25

Rebound. Naucast, a group company, and Insurance Rethink Honpo Group have announced a collaboration to utilize AI in the business activities of insurance brokers, which has attracted buying interest. They will introduce the AI-powered solution specialized in insurance broker business, 'Finatext Advisory Assist for Insurance Brokers', to 'Insurance Rethink Honpo', a nationwide insurance shop with over 350 stores, to improve the efficiency of sales operations and the quality of proposals.

<7097> Sakura Saku 1034 +20

Rebound. After the end of trading on the 4th, it was announced that YELL will acquire and make a subsidiary of the stock of "Mama Elle", a supplement product for women, and is considered as positive information. YELL has received high user ratings, and aims to further enhance its female care and femtech business by incorporating this excellent product line, contributing to women's health support. The acquisition price is undisclosed, but it is less than 15% of the consolidated net assets of 4.942 billion yen at the end of July 2023.

<5027> AnyMind 1303 +58

Rebound. It was announced that they will collaborate as a global marketing partner with SANDBOX, a creator management company in South Korea. In the Sandbox Network, they will provide solutions related to digital marketing from the formulation to the implementation of marketing strategies using AnyCreator and AnyTag. Creators affiliated with Sandbox can receive introductions to PR projects of brand companies and others through AnyCreator, and can utilize account analysis functions to increase revenue.

<6034> MRT 864 +150

Trading limit up. They announced that they have entered into a capital alliance with Docquity, which operates the largest physician platform in Southeast Asia. They will acquire a portion of the shares held by Itochu Corporation, the largest shareholder, and will enter into a capital alliance with Docquity under the support of Itochu Corporation, aiming to develop medical personnel introduction business in the Southeast Asian region and provide content to the group members of the company in Japan. The acquisition price of the newly acquired Docquity shares or equity holdings is 11,818,384 US dollars, which is 7.5% of the issued shares with voting rights.

Stock code 4576, DWTI, 82, +5

Significant rebound. The company has announced that the transplantation of the first subject in the phase II clinical trial of the regenerative medical cell product 'DWR-2206' (indication: bullous keratopathy) being developed in collaboration with Acturize has been conducted in Japan, and safety evaluation necessary for the continuation of the second and subsequent clinical trials has been obtained through the course observation. 'DWR-2206' is a cultured human corneal endothelial cell cryopreservation product that contains Rho kinase inhibitor, which is amplified and cultured outside the body, suspended in a cryopreservation solution, and injected into the anterior chamber to regenerate the corneal endothelium.

Stock code 4431, Sumareji, 2427, +45

Rebound. After the close of trading on the 4th, we announced the transition of the number of registered stores for the paid plan of the cloud POS register 'Sumareji' using tablets such as iPads, as well as the number of active stores (including free plans), and it has been well received. In August 24, the number of registered stores for the paid plan was a total of 37,936 (+545 compared to the previous month), and the number of active stores (including free plans) was a total of 45,810, showing a steady increase.